Marengo Therapeutics develops first-in-class therapeutics that activate selected Vβ T cell receptor variants to boost anti-tumor CD8+ and CD4+ T cell responses and promote long-term tumor immunity. Its proprietary Selective T Cell Activation Repertoire (STAR) platform mines an antibody library targeting diverse germline-encoded TCR Vβ variants to prime clonally diverse effector and memory T cells. The lead candidate, STAR0602, is an antibody fusion that cis-targets and activates a specific Vβ TCR subset while delivering additional signals to reprogram T cells for enhanced anti-tumor activity. The company reports reduced pro-inflammatory cytokine release with this approach, which may improve safety and tolerability. Marengo is advancing a broader pipeline of additional STAR programs to engage other immune cell types. The company intends to progress STAR0602 into the clinic in late 2022 for advanced and metastatic solid tumors.

Total raised

$80M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2021